Younger Onset of T2DM Linked to Increased Mortality Risk
FRIDAY, Feb. 23, 2018 -- Younger onset of type 2 diabetes is associated with increased mortality risk, mainly due to cardiovascular disease (CVD) mortality, according to a study published online Feb. 22 in Diabetologia.
Lili Huo, M.D., from Beijing Jishuitan Hospital, and colleagues examined data from 743,709 Australians with type 2 diabetes who were registered on the National Diabetes Services Scheme (NDSS) between 1997 and 2011. By linking the NDSS to the National Death Index, mortality data were derived; all-cause mortality and mortality due to CVD, cancer, and other causes were identified.
The researchers found that there were 115,363 deaths during 7.20 million person-years of follow-up. The rates of all-cause and cancer mortality declined and CVD mortality was constant during the first 1.8 years after diabetes diagnosis. There was an exponential increase in all mortality rates with age. Earlier diagnosis of type 2 diabetes correlated with increased risk of all-cause mortality, mainly driven by CVD mortality. There was a correlation for a 10-year earlier diagnosis of diabetes with a 1.2- to 1.3-times increased risk of all-cause mortality and about a 1.6-times increased risk of CVD mortality. Similar effects were seen in men and women. Earlier diagnosis of type 2 diabetes correlated with lower mortality due to cancer compared with diagnosis at an older age.
"Our findings suggest that younger-onset type 2 diabetes increases mortality risk, and that this is mainly through earlier CVD mortality," the authors write. "Efforts to delay the onset of type 2 diabetes might, therefore, reduce mortality."
© 2020 HealthDay. All rights reserved.
Posted: February 2018
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.